Get started
Author

Regina Michelle Stein

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
2018 · Cesar August Santa-Maria, Taigo Kato, et al. · Oncotarget · 135
PDF
The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias
2007 · Seema Singhal, Regina Stein, et al. · Blood · 30
PDF
Durvalumab and tremelimumab in metastatic breast cancer (MBC): Immunotherapy and immunopharmacogenomic dynamics.
2017 · Cesar Augusto Santa-Maria, Taigo Kato, et al. · Journal of Clinical Oncology · 26
Breaking Bad News in Breast Imaging: Keys to Success
2024 · Joshua Greenstein, Aja Green-Walker, et al. · Journal of Breast Imaging · 4
Gastrointestinal Malignancies
2011 · Maxwell T. Vergo, Regina M. Stein, et al. · Elsevier eBooks · 2
Abstract 4708: FGFR gene amplification and response to HER2-directed therapy in patients with HER2+ metastatic breast cancer (MBC)
2025 · Diana Jaber, Natalie K. Heater, et al. · Cancer Research · 1
Hereditary thrombotic thrombocytopenic purpura acquired through liver transplantation: A case report
2023 · Karlyn A. Martin, Anaadriana Zakarija, et al. · American Journal of Transplantation · 1
PDF
Diarrhea and Constipation: Supportive Oncology Management
2008 · Al B. Benson, Regina Stein · Humana Press eBooks · 1
Abstract PS5-01-21: Prognostic Significance of Circulating Tumor Cell Subtypes in HER2+ Metastatic Breast Cancer with Central Nervous System Metastases
2026 · D. Jaber, S. Marini, et al. · Clinical Cancer Research
Abstract P5-03-06: Correlation of Mutational Changes in Circulating Tumor DNA with Clinical Outcomes in HER2 Positive Metastatic Breast Cancer
2025 · Surbhi Warrior, Natalie K. Heater, et al. · Clinical Cancer Research
Abstract P5-03-08: Characteristics of ESR1-Mutant HER2 Positive Metastatic Breast Cancer (MBC)
2025 · Natalie Heater, Surbhi Warrior, et al. · Clinical Cancer Research
Abstract P2-07-16: Rising ESR1 Mutations in Circulating Tumor DNA (ctDNA) Mediate Endocrine Therapy (ET) Resistance to Everolimus and ET but Retain Sensitivity to Fulvestrant in HR+/HER2- Metastatic Breast Cancer (MBC)
2025 · Janice Lu, Qiang Zhang, et al. · Clinical Cancer Research
FGFR gene amplification and response to HER2-targeted therapy in patients with HER2-expressing metastatic breast cancer
2025 · Diana Jaber, Yangruijue Ma, et al. · Research Square
PDF
Characterization of the ctDNA mutational landscape in HER2-positive metastatic breast cancer patients who developed cancer therapy-related cardiac dysfunction.
2025 · Diana Alexandra Jaber, Natalie Knox Heater, et al. · Journal of Clinical Oncology
Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC).
2025 · Saranya Chumsri, Joyce O'Shaughnessy, et al. · Journal of Clinical Oncology
Association of circulating tumor cells with CNS metastatic patterns and survival outcomes in HER2+ metastatic breast cancer.
2025 · Diana Alexandra Jaber, Natalie Knox Heater, et al. · Journal of Clinical Oncology
Abstract LB408: Bria-ABC vs physician choice in late stage MBC: Early biomarker correlates of the randomized registration trial
2025 · Saranya Chumsri, Joyce A. OShaughnessy, et al. · Cancer Research
Abstract 1975: The use of circulating tumor DNA (ctDNA) in HER2+ metastatic breast cancer (MBC) for prognostication and management
2025 · Surbhi Warrior, Diana Jaber, et al. · Cancer Research
Barriers in time to initiation of therapy for newly prescribed novel oral oncolytics.
2017 · Christopher Tapia, Ann Andee Wang, et al. · Journal of Clinical Oncology
Contributors
2011 · Carla S. Alexander, Wendy G. Anderson, et al. · Elsevier eBooks
Gastrointestinal Malignancies
2007 · Al B. Benson, Regina M. Stein · Elsevier eBooks
Contributors
2007 · Carla S. Alexander, Wendy Gabrielle Anderson, et al. · Elsevier eBooks
Correlation of Serum Free Light Chain Levels with Other Parameters in Myeloma.
2006 · Regina Stein, Jayesh Mehta, et al. · Blood
Significance of Serum Free Light Chain Estimation with Detectable Serum Monoclonal Protein on Immunofixation Electrophoresis.
2006 · Jayesh Mehta, Regina Stein, et al. · Blood
The Serum Free Light Chain Assay Cannot Replace 24-Hour Urine Protein Estimation in Plasma Cell Dyscrasias.
2006 · Seema Singhal, Regina Stein, et al. · Blood
Works count: 27
Citation count: 200
H-index: 4
I10-index: 3
Year
Topic
Type